Introduction {#Sec1}
============

Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19), previously described as novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) \[[@CR1], [@CR2]\], occurred in Wuhan, China \[[@CR2]\]. COVID-19 is an acute resolved disorder but also lethal, with a 2% case mortality rate. Some studies have reported that the severity of some cases of COVID-19 mimicked that of severe acute respiratory syndrome (SARS) \[[@CR2]--[@CR4]\]. Thus, the World Health Organization (WHO) has declared the outbreak of COVID-19 a public health emergency of international concern \[[@CR5]\].

The initial diagnosis for suspected COVID-19 was on the basis of the SARS and Middle East respiratory syndrome (MERS) case diagnosis, as recommended by the WHO in 2003 and 2012, respectively \[[@CR6]--[@CR8]\]. During the initial phase of the COVID-19 outbreak, the diagnosis of the disease was complicated by the diversity in symptoms and imaging findings and in the severity of disease at the time of presentation. Currently, normal or low white blood cell count or low lymphocyte count is one of the diagnostic criteria for a suspected COVID-19 case. However, recent reports have showed that a proportion of patients with COVID-19 presented elevated white blood cell count in peripheral blood \[[@CR3], [@CR9]\]. Previous studies have reported the general epidemiological findings, clinical features and clinical outcomes of patients with COVID-19 \[[@CR2]--[@CR4]\]. However, specific information about patients with COVID-19 who have elevated leukocyte count remains unclear. Given no effective treatments or vaccines for COVID-19, the information on the clinical characteristics and outcomes of these cases might help understand the pathogenesis of the disease and improve clinical protocols against COVID-19. In this study, we describe the clinical characteristics in 52 hospitalized patients with COVID-19 who have elevated leukocyte count and compare them with patients who have no elevated leukocyte count in peripheral blood.

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

In this retrospective, single­centre study, all consecutive patients with confirmed COVID-19 admitted to Renmin Hospital of Wuhan University (Wuhan, China) from February 3 to March 3, 2020, were recruited. According to the assignments the Chinese Government, Renmin Hospital of Wuhan University is responsible for the treatments of adult patients with confirmed COVID-19 from the whole of Wuhan City. All patients with confirmed COVID-19 recruited in this study were diagnosed on the basis of WHO interim guidance \[[@CR10]\]. Other respiratory viruses including influenza A virus (H1N1, H3N2, H7N9), influenza B virus, respiratory syncytial virus, parainfluenza virus and adenovirus were also examined with real-time reverse transcriptase polymerase chain reaction (RT-PCR). Sputum or endotracheal aspirates were obtained at admission for identification of possible causative bacteria, tuberculosis or fungi. The patients with coinfections such as other viruses, bacteria, tuberculosis and fungi were excluded. Additionally, the patients who received systemic corticosteroids and antibiotics for treatment before admission were ineligible. Critically ill patients were identified as those admitted to the intensive care unit (ICU) who needed mechanical ventilation or required a fraction of inspired oxygen (FiO2) of at least 60% or more \[[@CR11]--[@CR13]\]. According to complete blood cell count at the time of admission, the patients with confirmed COVID-19 whose leukocyte count was more than 11,000 per mm^3^ were defined as the patient with increased leukocyte count, as previously reported \[[@CR14]--[@CR16]\], and other patients with confirmed COVID-19 whose leukocyte count was less than or equal to 11,000 per mm^3^ were defined as the patient with non-increased leukocyte count. Acute respiratory distress syndrome (ARDS) and shock were defined according to WHO interim guidance \[[@CR10]\]. Acute kidney injury was identified according to the Kidney Disease: Improving Global Outcomes definition \[[@CR17]\]. Secondary infection was diagnosed according to Center for Disease Control (CDC) definitions for nosocomial infections in 1988 \[[@CR18]\]. Systemic inflammatory response syndrome (SIRS) manifested by at least two of the following: (a) body temperature over 38 or under 36 degrees Celsius, (b) heart rate greater than 90 beats/min, (c) respiratory rate greater than 20 breaths/min or partial pressure of CO2 less than 32 mmHg or (d) leucocyte count greater than 12,000 or less than 4000/microliters or over 10% immature forms or bands \[[@CR19], [@CR20]\]. The study was approved by Renmin Hospital of Wuhan University Ethics Committee (No. WDRY2020-K143), and written informed consent was waived by the Ethics Commission.

Data collection {#Sec4}
---------------

Demographic data, exposure history, clinical symptoms or signs, chronic medical histories and laboratory findings at admission, treatment and clinical outcomes were collected from electronic medical records. All data were checked by two physicians. A patient of confirmed COVID-19 was defined as at least two positive results on the basis of RT-PCR assay of pharyngeal and nasal swab samples. Laboratory confirmation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was performed in Renmin Hospital of Wuhan University, a certified tertiary care hospital. RT-PCR measurements were performed according to a standard procedure recommended by Hubei Provincial CDC. Only laboratory-confirmed patients were enrolled to further analyse. Laboratory findings at admission included a complete blood cell count, blood biochemical analysis (including liver and renal function, lactate dehydrogenase), coagulation function testing and C-reactive protein (CRP), procalcitonin, arterial blood gas analysis and plasma cytokines such as IL-6. Additionally, all patients were given chest computed tomography (CT), and chest CT findings were reviewed by two physicians who extracted the data.

Clinical outcomes {#Sec5}
-----------------

The primary endpoints were the incidence of critically ill case, the incidence of SIRS and the complications (development of organ function damage). The secondary endpoints were the rate of admission to an ICU, and the rate of death. Clinical outcomes were followed up till March 22, 2020.

Statistical analysis {#Sec6}
--------------------

We present continuous measurements as mean (SD) if they are normally distributed or median (IQR) if they are not, and categorical variables as count (%). For laboratory results, we also assessed whether the measurements were outside the normal range. Independent group *t* tests were used for the comparison of means for continuous variables that were normally distributed; conversely, the Mann-Whitney *U* test was used for continuous variables not normally distributed. Proportions for categorical variables were compared using the χ2 test or Fisher's exact test. Two-sided *P* values of less than 0.05 were considered statistically significant. We used SPSS (version 26.0) for all analyses.

Results {#Sec7}
=======

Demographic data and clinical characteristics {#Sec8}
---------------------------------------------

As of Mar 3, 2020, a total of 619 patients with confirmed COVID-19 were enrolled. All patients had pneumonia with abnormal findings on chest CT scan. The patients with confirmed COVID were categorized as elevated leukocyte count in 52 patients, and non-increased leukocyte count in 567 patients (52 (8.4%) patients showed elevated leukocyte count) according to complete blood cell count at the time of admission. The demographic data and clinical characteristics of all patients were outlined in Table [1](#Tab1){ref-type="table"} and Table [2](#Tab2){ref-type="table"}. All patients were residents of Wuhan City. One hundred sixty-three (26.3%) had exposure to patients who had fever or respiratory symptoms. However, the exposure history between the two groups was similar. Compared with patients who had non-increased leukocyte count, patients who showed increased leukocyte count were significantly older (mean age, 64.7 years \[SD, 11.4\] vs 57.6 years \[SD, 13.0\]; *P* \< 0.01) and were more likely to have underlying comorbidities (37 \[71.2%\] patients and 260 \[45.9%\] patients, respectively; *P* \< 0.01), including hypertension (26 \[50%\] vs 139 \[24.5%\], diabetes (13 \[25.0%\] vs 72 \[12.7%\]), coronary heart disease (8 \[15.4%\] vs 37 \[6.5%\]) and cerebrovascular disease (2 \[3.8%\] vs 17 \[3.0%\]). The presence of fever was more common in patients with increased leukocyte count than those with non-increased leukocyte count at onset of illness (47 \[90.4%\] vs 425 \[75.0%\], *P* \< 0.05\]). Heart rate, respiratory rate and systolic pressure were significantly higher in patients with increased leukocyte count than those with non-increased leukocyte count on day of hospital admission (92 \[IQR, 82--107.5\], 23 \[IQR, 20--26\], 137.4 \[SD, 20.6\] and 80 \[IQR, 76--89\], 20 \[IQR, 19--22\], 125.6 \[SD, 12.7\] respectively; *P* \< 0.01).Table 1Demographic data and baseline characteristics in patients with COVID-19All patients (*n* = 619)Patients with increased leukocytes (*n* = 52)Patients with non-increased leukocytes (*n* = 567)*P* valueAge (years), mean ± SD58.2 ± 13.164.7 ± 11.457.6 ± 13.0\< 0.001  ≥ 60, n (%)275 (44.5)35 (67.3)240 (42.3)0.001  \< 60, n (%)344 (55.6)17 (32.7)327 (57.7)Sex  Female, n (%)310 (50.1)20 (38.5)290 (51.1)0.08  Male, n (%)309 (40.9)32 (61.5)277 (48.9)Current smoking, n (%)180 (29.1)13 (25)167 (29.5)0.499Exposure history, n (%)  Living in Wuhan City619 (100)52 (100)567 (100)  Contact with patients with fever or respiratory symptoms163 (26.3)14 (26.9)149 (26.3)0.92Underlying chronic disease, n (%)  Any297 (48.0)37 (71.2)260 (45.9)\< 0.001  Chronic obstructive pulmonary disease30 (4.8)3 (5.7)27 (4.8)0.732  Diabetes85 (13.7)13 (25)72 (12.7)0.014  Hypertension165 (26.7)26 (50)139 (24.5)\< 0.001  Coronary heart disease45 (7.3)8 (15.4)37 (6.5)0.043  Cerebrovascular disease19 (3.1)2 (3.8)17 (3.0)0.669  Tumour10 (1.6)1 (1.9)9 (1.6)0.587  Chronic renal disease28 (4.5)1 (1.9)27 (4.8)0.501    Immunodeficiency5 (0.8)05(0.9)1.00*COVID-19* coronavirus disease 2019Table 2Clinical characteristics and treatments in patients with COVID-19All patients (*n* = 619)Patients with increased leukocytes (*n* = 52)Patients with non-increase leukocytes (*n* = 567)*P* valueSymptoms and signs at admission, n (%)  Fever    Any472 (76.3)47 (90.4)425 (75.0)0.012    Highest temperature ≥ 39 °C134 (21.6)25 (48.1)109 (19.2)\< 0.001    Highest temperature \< 39 °C338 (54.6)22 (42.3)316 (55.7)0.063  Cough439 (70.9)41 (78.8)398 (70.2)0.189  Sputum production57 (9.2)11 (21.2)46 (8.1)0.002  Dyspnea105 (17.0)29 (55.8)76 (13.4)\< 0.001  Haemoptysis10 (1.6)2 (3.8)8 (1.4)0.202  Headache42 (6.79)9 (17.3)33 (5.8)0.005  Muscle ache51 (8.3)14 (26.9)37 (6.5)\< 0.001  Nausea and vomiting24 (3.9)3 (5.8)21 (3.7)0.444  Diarrhoea10 (1.6)2 (3.8)8 (1.4)0.202  Fatigue142 (22.9)35 (67.3)107 (18.9)\< 0.001  Rhinorrhoea27 (4.4)2 (3.8)25 (4.4)1.00  Sore throat61 (9.9)2(3.8)59 (10.4)0.129  Systolic pressure (mmHg), (mean ± SD)126.6 ± 13.9137.4 ± 20.6125.6 ± 12.7\< 0.001  Respiratory rate (breath/min), median (IQH)20 (19--23)23 (20--26)20 (19--22)\< 0.001    ≥ 20 breath/min, n (%)432 (69.8)47 (90.4)385 (67.9)0.001  Hearth rate(beat/min), median (IQH)81 (76--89)92 (82--107.5)80 (76--89)\< 0.001    ≥ 100 beat/min, n (%)77 (12.4)19(36.5)58 (10.2)\< 0.001Treatments, n (%)  Antiviral therapy559 (90.3)50 (95.6)509 (89.8)0.136  Antibiotic therapy441 (71.2)45 (86.5)396 (69.8)0.011  Systemic glucocorticoids219 (35.4)31 (59.6)188 (33.2)\< 0.001  Intravenous immunoglobulin113 (18.3)33 (63.5)80 (14.1)\< 0.001  Oxygen therapy338 (54.6)51 (98.1)287 (50.6)\< 0.001  Mechanical ventilator    Any83 (13.4)24 (46.2)59 (10.4)\< 0.001    Invasive15 (2.4)9 (17.3)6 (1.1)\< 0.001    Non-invasive68 (11.0)12 (23.1)56 (9.9)0.004    Use of ECMO3 (0.5)2 (3.8)1 (0.2)0.02*COVID-19* coronavirus disease 2019, *ECMO* extracorporeal membrane oxygenation

Radiologic and laboratory findings {#Sec9}
----------------------------------

The radiologic and laboratory findings of all patients were shown in Table [3](#Tab3){ref-type="table"}. All patients had unilateral or bilateral infiltrates on chest CT scan. However, radiologic findings did not differ between patients with increased leukocyte count and those with non-increased leukocyte count at the time of admission. Patients with increased leukocyte count had significantly prominent laboratory abnormalities than those with on-increased leukocyte count at admission. The blood levels of leukocyte count and neutrophil count, the serum concentrations of CRP and IL-6 were significantly increased in the patients with increased leukocyte count, compared with the patients with non-increased leukocyte count (11.96 \[IQR, 11.39--13.15\], 10.58 \[IQR, 9.58--12.22\], 78.7 \[IQR, 46.3--153.3\], 22.15 \[IQR, 11.94--67.79\] and 4.84 \[IQR, 3.85--5.74\], 3.18 \[IQR, 2.35--4.15\], 29.2 \[IQR, 5.0--64.4\] 8.40 \[IQR, 3.60--17.2\], respectively; *P* \< 0.01). Interestingly, the blood levels of leukocyte count and neutrophil count and the serum concentrations of CRP and IL-6 were significantly increased in the patients with increased leukocyte count who have underlying chronic diseases, compared with the patients with increased leukocyte count who have no underlying chronic diseases (12.30 \[IQR, 11.79--14.73\], 10.86 \[IQR, 9.92--13.31\], 91.4 \[IQR, 50.6--186.7\], 35.40 \[IQR, 15.94--83.00\] and 11.40 \[IQR, 11.22--12.54\], 9.99 \[IQR, 8.51--10.67\], 45.1 \[IQR, 6.8--107.7\], 14.27 \[IQR, 8.00--28.41\], respectively; *P* \< 0.05) (Table [4](#Tab4){ref-type="table"}).Table 3Laboratory and radiologic findings at admission in patients with COVID-19Normal rangeAll patients (*n* = 619)Patients with increased leucocytes (*n* = 52)Patients with non-increased leucocytes (*n* = 567)*P* valueBlood routine examinationLeukocytes, × 10^9^ per L3.5--9.55.02 (4.20--6.45)11.96 (11.39--13.15)4.84 (3.85--5.74)\< 0.001≥ 12, n (%)25 (4.0)25 (48.1)0 (0)\< 0.001\< 12, n (%)594 (96.0)27 (51.9)567 (100)Neutrophils, × 10^9^ per L1.8--6.33.34 (2.42--4.41)10.58 (9.58--12.22)3.18 (2.35--4.15)\< 0.001Haemoglobin, g/L,130--175122.77 ± 17.18126.52 ± 22.58122.42 ± 16.580.10Lymphocyte, × 10^9^ per L1.1--3.21.00 (0.68--1.36)0.75 (0.53--1.06)1.06 (0.68--1.37)\< 0.001Decreased, n (%)335 (54.1)40 (76.9)295 (52.0)0.001Activated partial thromboplastin time, S25.0--31.328 (26.4--30.0)27.4 (25.6--29.3)28.2 (26.4--30.1)0.063Increased, n (%)106 (17.1)6 (11.5)100 (17.6)0.264Decreased, n (%)62 (10.0)7 (13.5)55 (9.7)0.387D-Dimer, μg/L0.0--0.550.61 (0.36--1.63)7.49 (0.74--20.85)0.6 (0.34--1.48)\< 0.001Increased, n (%)350 (56.5)44 (84.6)306 (54.0)\<0.001Prothrombin time, S9.0--13.011.9 (11.4--12.6)12.7 (11.83--13.70)11.9 (11.3--12.5)\< 0.001Increased, n (%)106 (17.1)19 (36.5)87 (15.3)\< 0.001ALT, U/L9.0--50.028 (16--45)29 (20--51)28 (16--43)0.038Increased, n (%)144 (23.3)15 (28.8)129 (22.8)0.319AST, U/L15.0--40.027 (21--42)32 (24--56)27 (20--40)0.031Increased, n (%)160 (25.8)20 (38.5)140 (24.7)0.03Albumin, g/L40--55.037.6 (34.2--41.4)33.5 (31.5--37.5)37.8 (34.3--42.0)\< 0.001Decreased, n (%)402 (64.9)42 (80.8)360 (62.5)0.012Bun, mmol/L3.6--9.04.72 (363--6.70)7.50 (5.42--11.03)4.70 (3.60--6.44)\< 0.001Increased, n (%)104 (16.8)19 (36.5)85 (15.0)\< 0.001Decreased, n (%)121 (19.5)4 (7.7)117 (20.6)0.024Cr, umol/L41.0--73.063 (52--78)65 (51.3--80.5)63 (52--78)0.768Increased, n (%)173 (27.9)16 (30.8)157 (27.7)0.636LDH, U/L120--250272 (202--374)457.5 (306.3--688)265 (202--350)\< 0.001Increased, n (%)350 (56.5)45 (86.5)305 (53.8)\< 0.001Inflammation-associated biomarkersProcalcitonin, ng/mL\< 0.10.06 (0.04--0.11)0.21 (0.06--0.64)0.05 (0.04--0.11)\< 0.001Increased, n (%)183 (29.6)31 (59.6)152 (26.8)\< 0.001C-reactive protein, mg/L0--1029.7 (5--75.3)78.7 (46.3--153.3)29.2 (5.0--64.4)\< 0.001Increased, n (%)374 (60.4)44 (84.6)330 (58.2)\< 0.001Interleukin-6, mg/L≤ 20.09.40 (3.65--19.38)22.15 (11.94--67.79)8.40 (3.60--17.20)\< 0.001Increased, n (%)147 (23.7)27 (51.9)120 (21.2)\< 0.001Arterial blood gas analysisPH7.35--7.457.40 (7.37--7.43)7.41 (7.35--7.44)7.40 (7.37--7.43)0.525Increased, n (%)87 (14.1)10 (19.2)77 (13.6)0.262Decreased, n (%)69 (11.1)12 (23.1)57 (10.1)0.004PaCO2, mmHg33--4540 (36--44)40.5 (34.25--44.75)40 (36--44)0.89Increased, n (%)104 (16.8)7 (13.5)97 (17.1)0.501≤ 32 mmHg, n (%)78 (12.6)15 (28.8)63 (11.1)\< 0.001PaO2, mmHg80--10090 (74--98)67.5 (52--77.25)90 (75--101)\< 0.001≤60 mmHg, n (%)53 (8.6)19 (36.5)34 (6.0)\< 0.001Lactate, mmol/L0.5--1.62.1 (1.7--2.5)2.3 (1.7--3.3)2.1 (1.7--2.5)0.012Increased, n (%)480 (77.5)40 (80.7)440 (77.6)0.911Radiologic findingsUnilateral pneumonia, n (%118 (19.1)8 (15.4)110 (19.4)0.480Bilateral pneumonia, n (%)501 (80.9)44 (84.6)457 (80.6)Data are median (IQR) or n (%). Increased means over the upper limit of the normal range and decreased means below the lower limit of the normal range. *COVID-19* coronavirus disease 2019, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *Cr* creatinine, *BUN* blood urea nitrogen, *LDH* lactate dehydrogenase. *PaO2* arterial partial pressure of oxygen, *PCO2* arterial partial pressure of carbon dioxideTable 4Levels of leukocytes and neutrophils count, and inflammation-associated biomarkers in confirmed COVID-19 patient with underlying chronic disease at admissionNormal rangeAll patients\
(*n* = 52)Patients with underlying chronic disease (*n* = 37)Patients without underlying chronic disease (*n* = 15)*P* valueLeukocytes, × 10^9^ per L3.5--9.511.96 (11.39--13.15)12.30 (11.79--14.73)11.40 (11.22--12.54)0.007  ≥ 12, n (%)25 (48.1)20 (54.1)5 (33.3)0.175  \< 12, n (%)27 (51.9)17 (45.9)10 (66.7)Neutrophils, × 10^9^ per L1.8--6.310.58 (9.58--12.22)10.86 (9.92--13.31)9.99 (8.51--10.67)0.012  Increased, n (%)50 (96.2)37 (100)13 (86.7)0.079  Decreased, n (%)00(0)0(0)Procalcitonin, ng/mL\< 0.10.21 (0.06--0.64)0.23 (0.06--0.74)0.08 (0.06--0.59)0.613  Increased, n (%)31 (59.6)24 (64.9)7 (46.7)0.226C-reactive protein, mg/L0--1078.7 (46.3--153.3)91.4 (50.6--186.7)45.1 (6.8--107.7)0.010  Increased, n (%)44 (84.6)35 (94.6)9(60.0)0.005Interleukin-6, pg/mL≤ 20.022.15 (11.94--67.79)35.40 (15.94--83.00)14.27 (8.00--28.41)0.005  Increased, n (%)27 (51.9)23 (62.2)4 (26.7)0.02Data are median (IQR) or n (%). Increased means over the upper limit of the normal range and decreased means below the lower limit of the normal range. *COVID-19* coronavirus disease 2019

Treatment {#Sec10}
---------

All patients were treated in an isolation ward. The treatments of all patients were outlined in Table [2](#Tab2){ref-type="table"}. The use of antiviral treatment did not differ between patients with increased leukocyte count and those with non-increased leukocyte count at data cutoff. The administration of antibiotic therapy and systemic glucocorticoids was a higher percentage among patients with increased leukocyte count than those with non-increased leukocyte count (45 \[86.5%\], 31 \[59.6%\] and 396 \[69.8%\], 188 \[33.2%\], respectively; *P* \< 0.05). Oxygen therapy was administered in more patients with increased leukocyte count than in those with non-increased leukocyte count at data cutoff (51 \[98.1%\] and 287 \[50.6%\], respectively; *P* \< 0.01). Compared with patients with non-increased leukocyte count, patients with increased leukocyte count were more likely to receive mechanical ventilation, either invasively or noninvasively (9 \[17.3%\] vs 6 \[1.1%\] and 12 \[23.1%\] vs 56 \[9.9%\], respectively; *P* \< 0.01). Extracorporeal membrane oxygenation was performed in 2 patients (3.8%) with increased leukocyte count and in 1 patient (0.2%) with non-increased leukocyte count.

Clinical outcomes {#Sec11}
-----------------

The clinical outcomes of all patients were outlined in Table [5](#Tab5){ref-type="table"}. Compared with the patients with non-increased leukocyte count, the patients with increased leukocyte count were more likely to develop critically illness (26 \[50.0%\] patients and 74 \[13.1%\] patients, respectively; *P* \< 0.01), more likely to develop organ function damage(38 \[73.1%\] patients and 99 \[17.5%\] patients, respectively; *P* \< 0.01), especially ARDS (24 \[46.2%\] patients and 59 \[10.4%\] patients, respectively; *P* \< 0.01), more likely to admitted to an ICU (24 \[46.2%\] patients and 67 \[11.8%\] patients, respectively; *P* \< 0.01) and had a higher mortality rate (10 \[19.2%\] patients and 33 \[5.8%\] patients, respectively; *P* \< 0.01) at data cutoff. By the end of March 22, 451 (72.9%) patients had been discharged and 125 (20.2%) patients were still in hospital. Additionally, compared with the patients with non-increased leukocyte count, the patients with increased leukocyte count were more likely to develop SIRS (35 \[67.3%\] patients and 99 \[17.5%\] patients, respectively; *P* \< 0.01).Table 5Complications and clinical outcomes at data cutoff in patients with COVID-19Complications n (%)All patients (*n* = 619)Patients with increased leukocytes (*n* = 52)Patients with non-increase leukocytes (*n* = 567)*P* valueAny137 (22.1)38 (73.1)99 (17.5)\< 0.001Acute renal injury28 (4.5)9 (17.3)19 (3.4)\< 0.001Acute respiratory distress syndrome83 (13.4)24 (46.2)59 (10.4)\< 00.01Septic shock16 (2.6)5 (9.6)11(1.9)0.007Secondary infection46 (7.4)11 (21.2)35 (6.2)0.001  Other viruses6 (1.0)1 (1.9)5 (0.9)  Bacteria35 (5.7)7 (13.5)28 (1.9)  Fungus5 (1.0)2 (3.8)3 (0.5)Clinical outcomes, n (%)Incidence of SIRS134 (21.6)35 (67.3)99 (17.5)\< 0.001Incidence of critically illness100 (16.1)26 (50.0)74 (13.1)\< 0.001Admission to ICU91 (14.7)24 (46.2)67 (11.8)\< 0.001Discharge from hospital451 (72.9)32 (61.5)419 (73.9)0.055Death43 (6.9)10 (19.2)33 (5.8)0.002Hospitalization125 (20.2)10 (19.2)115 (20.3)0.857*COVID-19* coronavirus disease 2019, *ICU* intensive care unit, *SIRS* systemic inflammatory response syndrome

Discussion {#Sec12}
==========

The initial diagnostic criteria for suspected COVID-19 focused more on normal or low white blood cell count or low lymphocyte count of patients' peripheral blood \[[@CR9]\]. In this study, our data showed that lymphopenia was the most common laboratory abnormal finding in a cohort of 619 patients with confirmed COVID-19 who had pneumonia with abnormal features on chest CT scan, as previously reported \[[@CR2]--[@CR4]\]. However, 52 of 619 patients had increased leukocyte count at the time of admission in this study. Meanwhile, we found that the patients with increased leukocyte count were significantly older, and were more likely to have fever and underlying chronic diseases, thereby suggesting that the older patients with COVID-19 who had underlying chronic disorders are more likely to develop leukocytosis.

Studies of its effect on some body systems are important to the understanding of COVID-19. It is well known that SIRS is the systemic inflammatory response to a variety of severe clinical insults. Infection including virus infection is an important inducer of systemic inflammatory response \[[@CR19], [@CR20]\]. In this study, our data showed that the confirmed COVID-19 patients with increased leukocyte count were more likely to develop SIRS. Procalcitonin, IL-6 and CRP can be released in the acute phase of SIRS, as common biomarkers of SIRS \[[@CR20]--[@CR22]\]. Procalcitonin levels can mildly elevate in viral infection and significantly elevate in bacterial, fungal or parasitic infections \[[@CR20]\]. Both IL-6 and CRP are useful in predicting the severity and outcomes of SIRS \[[@CR22]--[@CR24]\]. Our present data indicated that the confirmed COVID-19 patients with increased leukocyte count exhibited increased concentrations of procalcitonin, CRP and IL-6 in the serum when compared with the patients with non-increased leukocyte count. Thus, our results suggested that the confirmed COVID-19 patients with increased leukocyte count had significantly higher level of systemic inflammation response, which at least partially related to the development of critical illness, with a high admission to an ICU and a high mortality rate. Interestingly, we found the blood levels of leukocyte count and neutrophil count, the serum concentrations of CRP and IL-6 were significantly increased in the patients with increased leukocyte count who have underlying chronic diseases, compared with the patients with increased leukocyte count who have no underlying chronic diseases. Therefore, our findings suggested that the systemic inflammatory response in the confirmed COVID-19 patients who had comorbidities was significantly higher than the patients who have no comorbidities. A growing body of evidences has suggested that chronic low-grade systemic inflammation was found in patients with underlying chronic diseases, such as diabetes \[[@CR25]\], cancer \[[@CR26]\] and metabolic syndrome (including hypertension) \[[@CR27]\]. Therefore, we speculated that the chronic low-grade systemic inflammation in confirmed COVID-19 patients who have underlying chronic diseases could promote systemic inflammatory response when SARS-CoV-2 infected.

In this study, our results showed that the confirmed COVID-19 patients with increased leukocyte count had a higher number of neutrophils in peripheral blood. As we discussed, the confirmed COVID-19 patients with leukocytosis had a higher level of systemic inflammatory response and IL-6 in the serum as comparison with the patients with non-increased leukocyte count. It has been reported that IL-6 can promote Th17 cells differentiation from naïve CD4 T cells \[[@CR28]--[@CR30]\], and Th17 cells can induce an inflammatory response through the production of IL-17A and IL-17F \[[@CR31]\], which act as key cytokines for neutrophils migration, recruitment and activation \[[@CR32], [@CR33]\]. It has been reported that phagocytosis, release of granular contents and production of cytokines are major effector functions of activated neutrophils, suggesting a protective immune response against the virus \[[@CR34]\]. However, excessive increased neutrophils can cause cytokine storm and tissue damage, leading to severe pneumonia and death \[[@CR34]\], which had been observed in patients with SARS \[[@CR35], [@CR36]\] and MERS \[[@CR37]\]. Therefore, it is possible that neutrophilia at least partially related to the development of critical illness, with a high admission to an ICU and a high mortality rate in the confirmed COVID-19 patients with increased leukocyte count. However, future studies to evaluate the mechanisms of these features may help us to understand this disorder.

In view of high level of inflammation-associated biomarkers, including neutrophil count and CRP in SARS-nCoV-2 infection, systemic glucocorticoids and antibiotics were frequently administrated for treatment of patients with COVID-19 in this study. However, our results showed that the confirmed COVID-19 patients with increased leukocyte count receiving antibiotics still had a considerable number of critical illness, with a high admission to an ICU and a high mortality rate. Therefore, antibiotic therapy and systemic glucocorticoids should not be routinely given for the confirmed COVID-19 patients with increased leucocyte count.

This study had several limitations, which might make some potential biases. First, it was a retrospective, single centre study and the sample size of confirmed COVID-19 patients with increased leukocyte count is small. It would be better for a multi-centre study including more patients to get a more comprehensive understanding of COVID-19. Second, among the 619 cases, 125 patients were still in hospital and the outcomes were unknown at data cutoff. Therefore, continued observations of the patients are needed. Third, some patients were given drug treatment before admission, which might affect laboratory findings. Despite that, our study demonstrated several novel clinical features in confirmed COVID-19 patients with increased leukocyte count.

In conclusion, leukocytosis is more likely to be observed in the older patients with COVID-19 who had underlying chronic disorders, and possibly result in critical illness, with a high admission to an ICU and a high mortality rate. Therefore, these patients need more intensive attention in the clinical practice.
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